8-K: Arrowhead Pharmaceuticals Secures First FDA Approval

Arrowhead Pharmaceuticals announced its 2025 fiscal year-end results, highlighted by the FDA approval of REDEMPLO, its first commercial-stage siRNA medicine for familial chylomicronemia syndrome (FCS).

Summary

• The U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
• This approval marks Arrowhead's first FDA-approved medicine, transitioning the company into a commercial-stage entity.
• REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and can be self-administered at home with a subcutaneous injection once every three months.
• The FDA approval is based on positive results from the Phase 3 PALISADE study, which showed REDEMPLO significantly reduced triglycerides by 80% from baseline and lowered the numerical incidence of acute pancreatitis compared to placebo.
• Arrowhead launched a 'One-REDEMPLO' pricing model and the 'Rely On REDEMPLO' patient support program.
• A global licensing and collaboration agreement was signed with Novartis for ARO-SNCA, a preclinical stage siRNA therapy for synucleinopathies like Parkinson's Disease, including a $200 million upfront payment and eligibility for up to $2 billion in development, regulatory, and sales milestone payments, plus tiered royalties.
• Regulatory clearance was filed to initiate Phase 1/2a clinical trials for ARO-DIMER-PA, an RNAi therapeutic for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia, designed to target two genes simultaneously.
• Regulatory clearance was also filed to initiate Phase 1/2a clinical trials for ARO-MAPT, an RNAi therapeutic for tauopathies including Alzheimer's disease, utilizing a new proprietary delivery system for CNS penetration.
• Arrowhead earned $300 million in milestone payments from Sarepta Therapeutics for ARO-DM1, an RNAi therapeutic for type 1 myotonic dystrophy, with $100 million satisfied by approximately $50 million in Arrowhead common stock and $50 million in cash.
• The first subject was dosed in the YOSEMITE Phase 3 clinical trial of zodasiran for homozygous familial hypercholesterolemia (HoFH), making it the fourth investigational RNAi-based candidate by Arrowhead to reach late-stage pivotal studies.
• Sanofi acquired an exclusive license from Visirna Therapeutics (a majority-owned Arrowhead subsidiary) for plozasiran in Greater China, including a $130 million upfront payment and eligibility for up to $265 million in further milestone payments.
• Revenue for the fiscal year ended September 30, 2025, was $829,448 thousand, a substantial increase from $3,551 thousand in the prior fiscal year.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. for fiscal year 2025 was $(1,631) thousand, a significant improvement from a net loss of $(599,493) thousand in fiscal year 2024.
• Diluted net loss per share attributable to Arrowhead Pharmaceuticals, Inc. was $(0.01) for fiscal year 2025, compared to $(5.00) in fiscal year 2024.
• Total cash resources (cash, cash equivalents, restricted cash, and available-for-sale securities) increased to $919,366 thousand as of September 30, 2025, from $680,961 thousand in the prior year.

Sentiment

Score: 9

Explanation: The filing reports a transformational FDA approval, significant revenue growth, a dramatic reduction in net loss, and substantial collaboration deals, indicating strong operational and strategic execution. While still reporting a net loss, the trajectory is overwhelmingly positive and signals a pivotal shift for the company.

Positives

• FDA approval of REDEMPLO (plozasiran) for FCS, marking the company's first commercial product and transition to a commercial-stage biopharmaceutical company.
• REDEMPLO is the first and only FDA-approved siRNA medicine for FCS, providing a novel treatment option for a severe, rare disease.
• Significant revenue growth to $829,448 thousand in FY2025 from $3,551 thousand in FY2024, driven by collaboration agreements and milestone payments.
• Dramatic reduction in net loss attributable to Arrowhead to $(1,631) thousand in FY2025 from $(599,493) thousand in FY2024, nearing profitability.
• Diluted net loss per share improved substantially to $(0.01) from $(5.00).
• Strong cash position with total cash resources increasing to $919,366 thousand as of September 30, 2025.
• Secured a $200 million upfront payment from Novartis for a global licensing and collaboration agreement, with potential for up to $2 billion in additional milestones and tiered royalties.
• Earned $300 million in milestone payments from Sarepta Therapeutics for ARO-DM1, demonstrating pipeline value.
• Strategic direct stock buyback of Arrowhead shares from Sarepta at $18.79 per share, reducing shares outstanding and indicating confidence in company valuation.
• Received a $130 million upfront payment from Sanofi for an exclusive license for plozasiran in Greater China, with potential for up to $265 million in further milestones.
• Advancement of multiple pipeline candidates into clinical trials (ARO-DIMER-PA, ARO-MAPT) and late-stage studies (zodasiran Phase 3), showcasing a robust and progressing pipeline.
• Introduction of a new proprietary delivery system for ARO-MAPT, demonstrating blood-brain-barrier penetration and deep knockdown in CNS in preclinical studies.

Negatives

• Despite significant revenue growth and improved financial performance, the company still reported a net loss attributable to Arrowhead of $(1,631) thousand for fiscal year 2025.
• Operating expenses increased significantly, with Research and development rising to $607,159 thousand from $505,870 thousand in the prior year, reflecting increased investment in pipeline development.
• General and administrative expenses also increased to $123,943 thousand from $98,761 thousand.
• Total other expense increased to $(46,813) thousand from $(11,380) thousand.

Risks

• The safety and efficacy of products and product candidates may not be fully established or maintained.
• Pricing and reimbursement decisions related to products could negatively impact commercial success.
• Demand for products may not meet expectations.
• Decisions of regulatory authorities and the timing thereof could affect product approvals and market access.
• The duration and impact of regulatory delays in clinical programs could extend development timelines and increase costs.
• The ability to finance operations may be challenged by future capital requirements.
• The likelihood and timing of the receipt of future milestone and licensing fees are uncertain.
• The future success of scientific studies is not guaranteed.
• The timing for starting and completing clinical trials is subject to various uncertainties.
• Rapid technological change in markets could render current technologies or products obsolete.
• The enforcement of intellectual property rights may be challenging or unsuccessful.

Future Outlook

Arrowhead Pharmaceuticals is well positioned to execute on aggressive goals in discovery, clinical development, business development, and commercialization to enable multiple potential new launches, both independently and with partners, over the coming years. The company believes in the long-term impacts of REDEMPLO (plozasiran) on patient health and the healthcare system, and the potential uses and value of its proprietary TRiM platform.

Management Comments

• "The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead."
• "REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and represents the first FDA-approval for a medicine leveraging Arrowhead's proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform."
• "However, Arrowhead is truly just getting started and we are well positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years."

Industry Context

The FDA approval of REDEMPLO positions Arrowhead as a commercial-stage company in the rapidly evolving RNAi therapeutic space, a field gaining significant traction for treating genetic and rare diseases. This approval, leveraging their TRiM platform, validates their technology and places them among leaders in gene silencing. Their collaborations with major pharmaceutical companies like Novartis and Sanofi, along with pipeline advancements in areas like Parkinson's, Alzheimer's, and cardiovascular disease, demonstrate a broad strategic approach to addressing intractable diseases, aligning with the industry trend of precision medicine and targeted therapies.

Comparison to Industry Standards

• REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS.
• REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS.
• ARO-DIMER-PA is the first clinical candidate to target two genes simultaneously in one molecule in the RNAi field.
• Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran (licensed to Takeda) and olpasiran (licensed to Amgen), indicating a strong track record in advancing candidates to pivotal trials compared to many biotech peers.

Stakeholder Impact

• Shareholders: Highly positive impact due to the FDA approval, significant revenue growth, reduced net loss, robust pipeline advancements, and strategic collaborations, which are likely to enhance shareholder value.
• Patients (FCS): Direct and immediate positive impact with the availability of REDEMPLO, the first and only FDA-approved siRNA medicine for FCS, offering a new and effective treatment option, supported by patient assistance programs.
• Patients (other diseases): Potential future benefits from the advancement of pipeline candidates for Parkinson's, Alzheimer's, atherosclerotic cardiovascular disease, homozygous familial hypercholesterolemia, and type 1 myotonic dystrophy.
• Employees: Positive impact from company growth, successful product launch, and expanded development activities, potentially leading to increased opportunities and stability.
• Partners (Novartis, Sarepta, Sanofi, Takeda, Amgen): Continued and strengthened collaboration, indicating mutual benefits and shared success in developing and commercializing innovative therapies.

Next Steps

• Commercialization and launch of REDEMPLO for familial chylomicronemia syndrome (FCS).
• Execution on aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years.
• Continued clinical development of ARO-SNCA in collaboration with Novartis for synucleinopathies.
• Initiation of Phase 1/2a clinical trials for ARO-DIMER-PA for atherosclerotic cardiovascular disease (ASCVD).
• Initiation of Phase 1/2a clinical trials for ARO-MAPT for tauopathies including Alzheimer's disease.
• Continued progress in the YOSEMITE Phase 3 clinical trial of zodasiran for homozygous familial hypercholesterolemia (HoFH).
• Development and commercialization of plozasiran in Greater China by Sanofi.

Key Dates

Recommendation

The FDA approval of REDEMPLO is a monumental achievement, transitioning Arrowhead into a commercial-stage company with a first-in-class product. This, combined with a dramatic increase in revenue, a near break-even net loss, and substantial upfront and milestone payments from strategic collaborations with major pharmaceutical partners (Novartis, Sarepta, Sanofi), demonstrates strong operational execution and validates their TRiM platform. The robust pipeline with multiple candidates in late-stage development and new targets entering clinical trials further de-risks future growth. The strategic stock buyback from Sarepta also indicates management's confidence in the company's valuation. These factors collectively point to significant future growth potential and make the stock highly attractive for long-term investors.

Keywords

Arrowhead Pharmaceuticals, ARWR, FDA approval, REDEMPLO, plozasiran, siRNA, familial chylomicronemia syndrome, FCS, TRiM platform, Novartis, ARO-SNCA, Parkinson's Disease, Sarepta Therapeutics, ARO-DM1, myotonic dystrophy, Sanofi, Visirna Therapeutics, ARO-DIMER-PA, atherosclerotic cardiovascular disease, ARO-MAPT, Alzheimer's disease, zodasiran, homozygous familial hypercholesterolemia, HoFH, RNAi, gene silencing, financial results, fiscal year 2025